Nuwellis to Participate in the AATS 106th Annual Meeting and ERAS Cardiac Spring Retreat

Nuwellis (Nasdaq: NUWE) will participate in the AATS 106th Annual Meeting May 2–5 in Chicago and attend the ERAS Cardiac Spring Retreat.

Rhea-AI Summary

Nuwellis (Nasdaq: NUWE) will participate in the AATS 106th Annual Meeting May 2–5 in Chicago and attend the ERAS Cardiac Spring Retreat. The company will showcase its Aquadex SmartFlow ultrafiltration system for fluid removal at Booth 530 and engage with cardiac surgery thought leaders.

Argus Apr 23 session

+3.89% close to close Open Argus

Details

News Market Reaction – NUWE

On Apr 23, the day this news came out, NUWE closed 3.89% above the previous close.

Data tracked by StockTitan Argus for the Apr 23 session.

Key Figures

Q4 2025 revenue: $2.4 million 2025 revenue: $8.3 million Q4 2025 gross margin: 68.2% +5 more

Q4 2025 revenue

$2.4 million

Q4 2025, up 4% YoY and 9% sequentially

2025 revenue

$8.3 million

Full year 2025, down 5% vs 2024

Q4 2025 gross margin

68.2%

Q4 2025, improved from 58.4%

2025 gross margin

62.0%

Full year 2025

Net loss 2025

$17.5 million

Full year 2025 net loss attributable to common shareholders

Cash at 12/31/25

$1.2 million

Cash, cash equivalents and restricted cash; no debt

Cash used in operations

$10.8 million

Cash used in operating activities during 2025

Potential warrant proceeds

$28 million

Maximum cash if all registered warrants exercised under S-3

Historical Context

5 past events · Latest: Apr 21

5 events

1. Apr 21

   Product update

   24h Move

   -0.9%

   Aquadex software update to enhance precision and usability, especially pediatrics.

2. Apr 16

   Hiring / staffing

   24h Move

   -2.9%

   Return of three commercial and clinical team members to support Aquadex growth.

3. Apr 9

   IR engagement

   24h Move

   +0.0%

   Engagement of CORE IR to expand market awareness and communications.

4. Apr 7

   Territory expansion

   24h Move

   +3.7%

   Creation of South Texas commercial territory to expand Aquadex access.

5. Mar 31

   Pediatric segment update

   24h Move

   +0.0%

   Pediatric category reaching ~50% of U.S. revenue and 47 centers footprint.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

ultrafiltration, cardiorenal, cardiothoracic, perioperative

4 terms

ultrafiltration medical

"showcase Aquadex ultrafiltration therapy for fluid removal in Booth 530"

Ultrafiltration is a process that separates small particles and liquids from larger molecules or substances using a filter with tiny pores. It is often used in water treatment and medical applications to remove impurities or excess fluids. For investors, understanding ultrafiltration is important because innovations or changes in this technology can impact industries focused on clean water, healthcare, and filtration products.

cardiorenal medical

"solutions for patients with cardiorenal conditions, announces it will participate"

Cardiorenal describes the close connection between the heart and kidneys, including conditions where disease in one organ directly affects the other — like a pump and filter that rely on each other to keep the system balanced. Investors care because treatments, diagnostics, or drugs that target this interaction can address multiple health problems at once, influencing market size, regulatory scrutiny, clinical trial complexity, and potential returns in healthcare and biotech sectors.

cardiothoracic medical

"AATS is one of the largest congresses in the cardiothoracic arena"

Cardiothoracic describes the medical specialty and treatments focused on the heart and the chest cavity, including the lungs, major blood vessels and the structures that surround them. For investors it identifies a market segment—surgeries, medical devices, drugs and hospital services—that is often high-cost, technology-driven and subject to regulatory and reimbursement changes; developments here can materially affect revenues, margins and risk for healthcare companies.

perioperative medical

"ERAS Cardiac is a nonprofit organization focused on enhancing perioperative care"

Pertaining to the entire span around a surgical operation — before, during and after the procedure — covering preparation, anesthesia, monitoring and recovery. Investors watch perioperative care because it shapes how often hospitals use devices, drugs and services, affects complication rates and patient stay length, and therefore influences revenue, costs and reimbursement risk; think of it like the full service cycle around a car repair that determines how long the shop is busy and what customers pay.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Medical technology company to showcase Aquadex ultrafiltration therapy for fluid removal in Booth 530

MINNEAPOLIS, April 23, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces it will participate in the AATS 106^th Annual Meeting taking place May 2–5 in Chicago. The Company will be showcasing its Aquadex SmartFlow® ultrafiltration system for fluid removal at Booth 530. At the start of the event, Nuwellis will attend the ERAS Cardiac Spring Retreat gathering of thought leaders, to discuss best practices and innovation in cardiac surgery care.

“AATS is one of the largest congresses in the cardiothoracic arena, and a unique opportunity to showcase our Aquadex technology, and discuss new updates, including ongoing advancements in precision ultrafiltration therapy,” said Nuwellls’ CEO John Erb. “At the ERAS Cardiac retreat, experts and thought leaders will discuss key issues facing practitioners today. Inclusion in this event is an important opportunity for Nuwellis to connect with industry colleagues in a lively dialogue, and we look forward to our annual participation.”

The AATS 106^th Annual Meeting is a premier cardiothoracic surgery event, bringing together leading experts from around the world to share best practices, explore cutting-edge innovations, and advance the field. ERAS Cardiac is a nonprofit organization focused on enhancing perioperative care in adult cardiac surgery.

For more information on the AATS 106^th Annual Meeting, visit the event’s website.

About Nuwellis

Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company committed to delivering solutions for patients with cardiorenal conditions. The Company develops solutions designed to support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings. Nuwellis’ portfolio includes commercially available and development-stage technologies addressing complex cardiorenal conditions, with a focus on safety, precision, and scalability across patient populations. For more information, visit www.nuwellis.com.

Forward-Looking Statements

Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2026 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.

For further information, please contact:

Investor Relations:
ir@nuwellis.com

Media Contact:

CORE PR
media@nuwellis.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Nuwellis (NUWE) present at the AATS 106th Annual Meeting in 2026?

Nuwellis will participate at AATS from May 2–5, 2026. According to the company, representatives will showcase Aquadex at Booth 530 and attend the ERAS Cardiac Spring Retreat at the start of the event.

What will Nuwellis (NUWE) exhibit at Booth 530 during AATS 2026?

Nuwellis will display the Aquadex SmartFlow ultrafiltration system for fluid removal. According to the company, the exhibit highlights ongoing advancements in precision ultrafiltration therapy for cardiorenal patients.

What is the purpose of Nuwellis attending the ERAS Cardiac Spring Retreat at AATS 2026?

Nuwellis will attend to engage with experts on perioperative and cardiac surgery best practices. According to the company, the retreat gathers thought leaders to discuss innovation and clinical care improvements.

How can investors or clinicians find Nuwellis at the AATS 106th Annual Meeting?

Visit Booth 530 during AATS May 2–5 to see Aquadex demonstrations. According to the company, event participation offers opportunities for dialogue with industry peers and product overview sessions.